AVE 0.00% 0.2¢ avecho biotechnology limited

neura therapeutik news, page-12

  1. 1,912 Posts.
    lightbulb Created with Sketch. 214
    follow on Jev from your thought

    either a ridiculous co-incidence if it was another product with POH the only partner as you say on the website and POH being nearly ready.

    but also all the following elements -

    "Achieving a balance between pain control and minimizing the risks of abuse." ? isn't this the time release properties of an abuse proof patch.


    "It has physical barriers that prevent chewing, crushing, grating or grinding" ? wouldn't that be the polymer patch

    "Its chemical barriers resist extraction of the opioid using common household solvents or co-ingesting with alcohol" ? wouldn't that relate SOMEWHAT to the 6 months stability delay

    the one concerning element of the statement for me is this

    "In addition, its key differentiating feature compared to other abuse-deterrent formulations is its ability to retain its extended-release properties even when crushed" ? it seems an odd statement.

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.